☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search category
Search here
Search here
Subscribe Now
C. difficile
Finch Therapeutics' CP101 Receives FDA's Breakthrough Therapy Designation (BT) for Recurrent Clostridium Difficile (C. difficile)...
February 11, 2019
Load more...
Back to Home